Guggenheim reaffirmed their buy rating on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research report released on Friday, Benzinga reports. They currently have a $56.00 price target on the stock. Several other brokerages have also commented on VERA. Raymond James raised Vera Therapeutics from an outperform rating to a strong-buy rating and […]
Related Keywords
Raymond James , Maha Katabi , Cantor Fitzgerald , Barclays Plc , Vanguard Group Inc , Capital Partners , Goldman Sachs Group Inc , Vera Therapeutics Inc , Vera Therapeutics , Free Report , Director Maha Katabi , Sachs Group , Get Free Report , Vera Therapeutics Daily , Nasdaq Vera , Vera , Medical , Reiterated Rating , Guggenheim ,
vimarsana.com © 2020. All Rights Reserved.